Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death

Imatinib targets Bcr-Abl, the causative event of chronic myelogenous leukemia (CML), and addresses leukemic cells to growth arrest and cell death. The exact mechanisms responsible for imatinib-induced cell death are still unclear. We investigated the role of poly(ADP-ribose) polymerase (PARP) activity in imatinib-induced cell death in Bcr-Abl-positive cells. Imatinib leads to a rapid increase of poly(ADP-ribosyl)ation (PAR) preceding loss of integrity of mitochondrial membrane and DNA fragmentation. The effect of imatinib on PAR can be mimicked by inhibition of phosphatidylinositol 3-kinase (PI3-K) implicating a central role of the PI3-K pathway in Bcr-Abl-mediated inhibition of PAR. Importantly, inhibition of PAR in imatinib-treated cells partially prevented cell death to an extent comparable to that observed after caspase inhibition. Simultaneous blockade of both caspases and PAR revealed additive cytoprotective effects indicating that both pathways function in parallel. In conclusion, our results suggest that in addition to the well-documented caspase-dependent pathway, imatinib also induces a PARP-mediated death process.

[1]  C. Peschel,et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.

[2]  C. Miething,et al.  Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. , 2001, Blood.

[3]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[4]  M. Greaves,et al.  Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia , 1987, Nature.

[5]  R. Chopra,et al.  Biology of BCR-ABL. , 1999, Blood reviews.

[6]  T. Tsuruo,et al.  Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148 , 1998, Cell Death and Differentiation.

[7]  F. Cecconi,et al.  Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak‐mediated permeabilization , 2003, The EMBO journal.

[8]  G. Daley,et al.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[9]  I. Sánchez-García,et al.  Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. , 1997, Journal of molecular biology.

[10]  A. Bürkle.  Physiology and pathophysiology of poly(ADP‐ribosyl)ation * , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[11]  E. Jacobson,et al.  ADP-ribose Polymer Metabolism: Implications for Human Nutrition , 1992 .

[12]  C. L. Perkins,et al.  CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. , 2000, Blood.

[13]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[15]  M. Malanga,et al.  Recombinant IFN-alpha2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells. , 2003, European Journal of Cancer.

[16]  A. Bürkle,et al.  Poly(ADP‐ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditions , 2004, International journal of cancer.

[17]  Razelle Kurzrock,et al.  Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics , 2003, Annals of Internal Medicine.

[18]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[19]  M. Hallek,et al.  The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  K. Fukuchi,et al.  Phosphatidylinositol 3-kinase inhibitors, Wortmannin or LY294002, inhibited accumulation of p21 protein after gamma-irradiation by stabilization of the protein. , 2000, Biochimica et biophysica acta.

[21]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[22]  M. Hallek,et al.  Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. , 2000, Blood.

[23]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[24]  C. Szabó,et al.  Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. , 1998, Journal of immunology.

[25]  T. Dawson,et al.  Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor , 2002, Science.

[26]  O. Witte,et al.  The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc , 1989, Molecular and cellular biology.

[27]  M. Hallek,et al.  The Tyrosine Kinase Inhibitor CGP 57148 ( ST 1 571 ) Induces Apoptosis in BCR-ABL-positive Cells by Down-Regulating BCL-X 1 , 2000 .

[28]  M. Oren,et al.  Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. , 2001, Cancer research.

[29]  G. Kroemer,et al.  A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. , 2004, Blood.

[30]  N. Berger.  Poly(ADP-ribose) in the cellular response to DNA damage. , 1985, Radiation research.

[31]  G. Poirier,et al.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.

[32]  E. Sausville,et al.  Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. , 2002, Blood.

[33]  B. Zehnbauer,et al.  Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.

[34]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[35]  Y Taya,et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.

[36]  N. Mivechi,et al.  Role of ERK activation in growth and erythroid differentiation of K562 cells. , 2001, Experimental cell research.

[37]  C. Verfaillie,et al.  Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. , 1992, The Journal of clinical investigation.

[38]  Jon C. Aster,et al.  Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow , 1998 .

[39]  M. Ogura,et al.  Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. , 1985, Blood.

[40]  P. Laneuville,et al.  bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. , 1994, Cancer research.

[41]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[42]  J. Griffin,et al.  Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. , 1996, The Journal of clinical investigation.

[43]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[44]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[45]  G. Kroemer,et al.  Mitochondria, AIF and caspases — rivaling for cell death execution , 2003, Nature Cell Biology.

[46]  C. Szabó,et al.  Poly(ADP-ribose) polymerase inhibitors. , 2003, Current medicinal chemistry.

[47]  J. Aster,et al.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. , 1998, Blood.

[48]  Soldatenkov Va,et al.  DNA-Binding Properties of Poly(ADP-Ribose) Polymerase: A Target for Anti-Cancer Therapy , 2004 .

[49]  C. Miething,et al.  Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines. , 2004, Leukemia research.

[50]  P. Bernardi,et al.  Opening of the Mitochondrial Permeability Transition Pore Causes Depletion of Mitochondrial and Cytosolic NAD+and Is a Causative Event in the Death of Myocytes in Postischemic Reperfusion of the Heart* , 2001, The Journal of Biological Chemistry.

[51]  V. Potaman,et al.  DNA-binding properties of poly(ADP-ribose) polymerase: a target for anticancer therapy. , 2004, Current drug targets.

[52]  J. Lis,et al.  PARP Goes Transcription , 2003, Cell.

[53]  R. Swanson,et al.  Poly(ADP-ribose) Polymerase-1-mediated Cell Death in Astrocytes Requires NAD+ Depletion and Mitochondrial Permeability Transition* , 2004, Journal of Biological Chemistry.

[54]  O. Witte,et al.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[55]  T. Dawson,et al.  Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. , 2004, Trends in pharmacological sciences.